The British Journal of Cardiology

This site is intended for UK healthcare professionals

 
BJC_tv_logo_white
Sign in

The COVID-19 cardiovascular legacy: long COVID and its complications

30 April 2024
COVID-19, and specifically long COVID, is associated with an increased risk of cardiovascular disease. Listen as Professor Banerjee describes his work in this area, especially the STIMULATE-ICP trial, which looks at long COVID’s physiological and social impact. Find out about what the NHS is doing to tackle COVID-19 and its associated cardiovascular and metabolic abnormalities.

Speakers

Amitava Banerjee, Professor of Clinical Data Science, University College London, and Honorary Consultant Cardiologist, UCLH and Barts Health NHS Trust

 

Learning objectives
  • Learn how cardiovascular disease is both a risk factor and an outcome of the COVID-19 infection.
  • Know the evidence behind multi-organ and metabolic damage in long COVID,  as well as the prevention of long COVID.
  • Understand the clinical trials that have successfully incorporated a learning health system approach to improve the recovery of people living with long COVID.

Categories

Tags

blank

ESC Congress 2024 highlights – A UK perspective: What’s new in the latest ESC guideline update?

  • Paul Foley, Terry McCormack

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.

blank

ESC Congress 2024 highlights – A UK perspective: New evidence on cardiovascular medical care

  • Sarah Birkhoelzer, Aaron Henry

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.

blank

© 2024 Medinews Cardiology Ltd, a wholly-owned subsidiary of OmniaMed Communications Ltd   |   Privacy & cookies policy   |   Terms & conditions

 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.